1. Show article details.

    BRIEF-Ocugen Inc Announces The Cancellation Of Stockholder Meeting Previously Adjourned To 1100 A.M. ET On Jan. 13, 2021

    Reuters – 7:57 AM ET 01/12/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN). ANNOUNCES THE CANCELLATION OF STOCKHOLDER MEETING PREVIOUSLY ADJOURNED TO 11:00 A.M. EASTERN TIME ON JANUARY 13, 2021 Source text for Eikon: Further company coverage:

  2. Show article details.

    Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021

    GlobeNewswire – 7:52 AM ET 01/12/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced it has determined to withdraw from stockholder consideration Item 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on October 30, 2020, with respect t...

  3. Show article details.

    BRIEF-Ocugen Inc. Regains Compliance With Nasdaq Bid Price Rule

    Reuters – 3:17 PM ET 01/08/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN). REGAINS COMPLIANCE WITH NASDAQ BID PRICE RULE Source text for Eikon: Further company coverage:

  4. Show article details.

    Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule

    GlobeNewswire – 3:17 PM ET 01/08/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq Stock Market LLC that the Company has regained compliance with Listing Rule 5550.

  5. Show article details.

    Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences

    GlobeNewswire – 8:00 AM ET 01/08/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC 5th Healthcare Investment Summit being held on January 9-10, the H.C. Wainwright BioConnect Conference being held on January 11-14, and the Noble Capital Markets ...

  6. Show article details.

    India's approval of homegrown vaccine criticised over lack of data

    Reuters – 6:50 AM ET 01/03/2021

    * Emergency-use approval for Bharat's COVAXIN. * Government also approved use of AstraZeneca/Oxford vaccine. * AstraZeneca/Oxford shot to lead immunisation programme. By Krishna N. Das. India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.

  7. Show article details.

    TIMELINE-India's coronavirus vaccine approved by drugs experts

    Reuters – 1:41 PM ET 01/02/2021

    India's drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot. COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research. Not much is known about the safety and efficacy of COVAXIN.

  8. Show article details.

    Ocugen Establishes Vaccine Scientific Advisory Board

    GlobeNewswire – 7:15 PM ET 12/23/2020

    Ocugen, Inc. (OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-v...

  9. Show article details.

    Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

    GlobeNewswire – 9:07 PM ET 12/22/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will convene its 2020 Annual Meeting of Stockholders on December 23, 2020 at 11:00 a.m. Eastern time and, after conducting all other business, intends to adjourn the meeting solely with respect to Item 2 set forth in its D...

  10. Show article details.

    BRIEF-Ocugen And Bharat Biotech To Co-Develop Covaxin, A Covid-19 Vaccine, For The Us Market

    Reuters – 8:34 AM ET 12/22/2020

    Ocugen Inc (OCGN): * OCUGEN AND BHARAT BIOTECH TO CO-DEVELOP COVAXIN™, A WHOLE-VIRION INACTIVATED COVID-19 VACCINE, FOR THE US MARKET. * Ocugen Inc (OCGN) - VACCINE CANDIDATE IS AN INACTIVATED TYPE VACCINE. * Ocugen Inc (OCGN) - VACCINE CANDIDATE IS CURRENTLY PART OF A PHASE 3 CLINICAL TRIAL IN INDIA INVOLVING 26,000 VOLUNTEERS. * Ocugen Inc (OCGN) - OCUGEN WILL HAVE U.S. RIGHTS TO VACCINE CANDIDATE.

  11. Show article details.

    Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S.

    Reuters – 7:44 AM ET 12/22/2020

    Drug developer Ocugen Inc (OCGN) will co-develop India-based Bharat Biotech's COVID-19 vaccine candidate for the U.S. market, the companies said on Tuesday. The vaccine candidate, Covaxin, is currently in a late-stage study in India.

  12. Show article details.

    Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market

    GlobeNewswire – 7:30 AM ET 12/22/2020

    Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2 trials Vaccine candidate is an inactivated type vaccine with potentially broad appeal MALVERN, Pa. and HYDERABAD, India, Dec. 22, 2020 -- Ocugen, Inc. (OCGN), a leading biopharmaceutical company, and Bharat Biotec...

  13. Show article details.

    BRIEF-Ocugen Announces Plan To Postpone Annual Meeting Of Stockholders

    Reuters – 5:47 PM ET 12/10/2020

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN). ANNOUNCES PLAN TO POSTPONE ANNUAL MEETING OF STOCKHOLDERS. * OCUGEN (OCGN) - WILL POSTPONE 2020 ANNUAL MEETING OF STOCKHOLDERS TO DECEMBER 23 TO PROVIDE ITS STOCKHOLDERS ADDITIONAL TIME TO VOTE ON PROPOSALS SUBMITTED Source text for Eikon: Further company coverage:

  14. Show article details.

    Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders

    GlobeNewswire – 5:44 PM ET 12/10/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020 to provide its stockholders additional time to vote on the proposals submitted for stockholder approval at the meeting.

  15. Show article details.

    Advanced Testing Options Help Alter the Fight Against Cancer

    PR Newswire – 9:00 AM ET 12/09/2020

    NEW YORK, Dec. 9, 2020 The global biopharmaceutical market is driven by many complex factors. The biopharmaceutical market plays a major role in the cancer treatment industry, which has grown to be one of the largest marketplaces in the world due to the disease's global prevalence.

  16. Show article details.

    BRIEF-Ocugen Says ISS And Glass Lewis Recommend Stockholders Vote "For" Reverse Stock Split And Authorized Shares Amendment Proposals

    Reuters – 6:26 PM ET 12/01/2020

    Ocugen Inc (OCGN): * LEADING INDEPENDENT PROXY FIRMS ISS AND GLASS LEWIS RECOMMEND OCUGEN STOCKHOLDERS VOTE “FOR” REVERSE STOCK SPLIT AND AUTHORIZED SHARES AMENDMENT PROPOSALS Source text for Eikon: Further company coverage:

  17. Show article details.

    Leading Independent Proxy Firms ISS and Glass Lewis Recommend Ocugen Stockholders Vote “FOR” Reverse Stock Split and Authorized Shares Amendment Proposals

    GlobeNewswire – 5:53 PM ET 12/01/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, the nation’s leading independent proxy advisory firms, have recommended that Ocugen (OCGN) stockholders vote “FOR” both Proposals 1 and 2 at the Company’s ...

  18. Show article details.

    CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies

    GlobeNewswire – 8:09 AM ET 11/27/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen (OCGN), will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Ev...

  19. Show article details.

    BRIEF-Ocugen Reports Q3 Loss Per Share $0.07

    Reuters – 7:45 AM ET 11/06/2020

    Ocugen Inc (OCGN): * Q3 LOSS PER SHARE $0.07. * Q3 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA. * EXTENDED CASH RUNWAY FOR CONTINUED DEVELOPMENT OF PRODUCT CANDIDATES Source text for Eikon: Further company coverage:

  20. Show article details.

    Ocugen Provides Business Update and Third Quarter 2020 Financial Results

    GlobeNewswire – 7:30 AM ET 11/06/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness diseases, today reported third quarter 2020 financial results along with a general business update. “I am proud of the advancements we have made this quarter in developing our modifier gene therapy and novel biologic product candidates.

Page:

Today's and Upcoming Events

  • Mar
    25

    OCGN to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    06

    OCGN announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.